Hastings Center Report
Sickle Cell Gene Therapy: Promise, Limits, and the Ethics of “Cure”
The approval of gene therapies for sickle cell disease marked a radical scientific innovation for patients, but the authors of a new essay in the Hastings Center Report warn that calling these therapies a “cure” is misleading. While they can generate healthy, or nonsickled, red blood cells and reduce acute symptoms, they don’t eliminate chronic pain, organ damage, stigma, or the long-term social and psychological toll of the disease.
In addition, many with sickle cell disease—who are disproportionately Black—experience ongoing discrimination in medical settings, including skepticism about their pain. Using curative language can misrepresent ongoing physical, psychological, and social challenges patients face, even after treatment. One of the authors is Jada Wiggleton-Little, an inaugural Hastings Center Sadler Scholar.
Key Takeaways
- Gene therapy is a breakthrough, not a cure.
- Cost, access, and equity remain major ethical challenges.
- Honest framing is key to addressing health inequities.
